MX2007011571A - Derivado de quinona 2,3-dimetoxi-5-metil-6-(10-hidroxidecil)-1,4- benzoquinona para el tratamiento de distrofias musculares. - Google Patents

Derivado de quinona 2,3-dimetoxi-5-metil-6-(10-hidroxidecil)-1,4- benzoquinona para el tratamiento de distrofias musculares.

Info

Publication number
MX2007011571A
MX2007011571A MX2007011571A MX2007011571A MX2007011571A MX 2007011571 A MX2007011571 A MX 2007011571A MX 2007011571 A MX2007011571 A MX 2007011571A MX 2007011571 A MX2007011571 A MX 2007011571A MX 2007011571 A MX2007011571 A MX 2007011571A
Authority
MX
Mexico
Prior art keywords
hydroxydecyl
benzoquinone
dimethoxy
methyl
treatment
Prior art date
Application number
MX2007011571A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Meier
Gunnar Buyse
Original Assignee
Santhera Pharmaceuticals Ch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36572153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007011571(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santhera Pharmaceuticals Ch filed Critical Santhera Pharmaceuticals Ch
Publication of MX2007011571A publication Critical patent/MX2007011571A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2007011571A 2005-03-21 2006-03-20 Derivado de quinona 2,3-dimetoxi-5-metil-6-(10-hidroxidecil)-1,4- benzoquinona para el tratamiento de distrofias musculares. MX2007011571A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05006137 2005-03-21
PCT/EP2006/002536 WO2006100017A1 (en) 2005-03-21 2006-03-20 Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies

Publications (1)

Publication Number Publication Date
MX2007011571A true MX2007011571A (es) 2007-12-06

Family

ID=36572153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007011571A MX2007011571A (es) 2005-03-21 2006-03-20 Derivado de quinona 2,3-dimetoxi-5-metil-6-(10-hidroxidecil)-1,4- benzoquinona para el tratamiento de distrofias musculares.

Country Status (17)

Country Link
US (1) US7977388B2 (https=)
EP (1) EP1861080B1 (https=)
JP (1) JP4896123B2 (https=)
AT (1) ATE468849T1 (https=)
AU (1) AU2006226623B2 (https=)
CA (1) CA2602290C (https=)
CY (1) CY1110182T1 (https=)
DE (1) DE602006014514D1 (https=)
DK (1) DK1861080T3 (https=)
ES (1) ES2345353T3 (https=)
MX (1) MX2007011571A (https=)
NZ (1) NZ561235A (https=)
PL (1) PL1861080T3 (https=)
PT (1) PT1861080E (https=)
SI (1) SI1861080T1 (https=)
WO (1) WO2006100017A1 (https=)
ZA (1) ZA200707833B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103271935A (zh) 2006-08-01 2013-09-04 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
EP1891946A1 (en) * 2006-08-14 2008-02-27 Santhera Pharmaceuticals (Schweiz) AG Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone
WO2009079562A2 (en) 2007-12-17 2009-06-25 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
SI2108366T1 (sl) * 2008-04-09 2012-01-31 Santhera Pharmaceuticals Ch Idebenon za zdravljenje respiratorne bolezni pri miĺ iäśni distrofiji
EP2246048A1 (en) 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
DK2605769T3 (en) 2010-08-16 2016-10-24 Santhera Pharmaceuticals (Schweiz) Ag Benzoquinonderivater for the treatment of mitochondrial diseases of the eye
CN103086861B (zh) * 2012-11-12 2015-09-16 刘炜 羟癸基苯醌衍生物及其用途
US20230047313A1 (en) * 2019-12-16 2023-02-16 Children`S Medical Center Corporation Treating heart disease in muscular dystrophy patients
EP4351545A1 (en) 2021-06-07 2024-04-17 Katholieke Universiteit Leuven Idebenone in the treatment of drug resistant epilepsy
CN113827585B (zh) * 2021-10-27 2023-04-11 山东大学齐鲁医院 艾地苯在治疗肢带型肌营养不良2g型中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8562998A (en) 1997-08-12 1999-03-01 Takeda Chemical Industries Ltd. Idebenone-containing preparation for percutaneous administration
JPH11116470A (ja) 1997-08-12 1999-04-27 Takeda Chem Ind Ltd イデベノン含有経皮投与製剤
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US20040081961A1 (en) * 2001-05-04 2004-04-29 Delegeane Angelo M Proteases
EP1618881A1 (en) 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy

Also Published As

Publication number Publication date
DE602006014514D1 (https=) 2010-07-08
AU2006226623B2 (en) 2010-04-22
WO2006100017A1 (en) 2006-09-28
PL1861080T3 (pl) 2010-10-29
ATE468849T1 (de) 2010-06-15
PT1861080E (pt) 2010-06-17
SI1861080T1 (sl) 2010-08-31
JP2008533182A (ja) 2008-08-21
CY1110182T1 (el) 2015-01-14
US20090012050A1 (en) 2009-01-08
EP1861080B1 (en) 2010-05-26
US7977388B2 (en) 2011-07-12
NZ561235A (en) 2010-12-24
EP1861080A1 (en) 2007-12-05
CA2602290A1 (en) 2006-09-28
DK1861080T3 (da) 2010-09-06
ES2345353T3 (es) 2010-09-21
JP4896123B2 (ja) 2012-03-14
AU2006226623A1 (en) 2006-09-28
CA2602290C (en) 2012-01-17
ZA200707833B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
ZA200707833B (en) Quinone derivative 2,3-dimethoxy-5-methyl-6-(-10-hydroxydecyl)-1,4-benzoquinone for the treatment of muscular dystrophies
WO2004004658A3 (en) Methods and compositions relating to isoleucine boroproline compounds
TW200640488A (en) Extending time to disease progression or survival in cancer patients
WO2010009892A8 (en) Compositions for the treatment of pain and/or inflamation
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
IL232313A (en) Modulators of indoleamine 2,3-dioxigenase and methods of use of the above
MX2009012558A (es) Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne.
EP1991218A4 (en) USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
WO2006133022A3 (en) Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2007146426A3 (en) Nanoshells for drug delivery
WO2009032888A3 (en) Method for providing energy, relieving stress and mood enhancing benefits comprising administering a composition comprising cholecalciferol and a tea extract
MY148723A (en) Use of pinolenic acid for the treatment of obesity
WO2007079146A8 (en) Treatment for non-hodgkin's lymphoma
ZA201006905B (en) Quinone derivative 2,3-dimerhoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of respiratory illness in muscular dystrophy
WO2005089515A3 (en) Methods for the treatment of synucleinopathies
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
PL2193789T3 (pl) Zastosowanie 5-metylo-1,3-benzenodiolu lub jego pochodnych w przygotowaniu leku i funkcjonalnej żywności do leczenia lub zapobiegania depresji
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
AP2010005435A0 (en) 1,4-Naphthoquinone derivatives and therapeutic usethereof.
WO2005089496A3 (en) Methods for the treatment of synucleinopathies
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
IL200192A (en) Use of l-cannitin and / or alkonial l-carnitine, or their common pharmaceutical salt, in combination with statin, for the preparation of a drug for the treatment of type 2 diabetes
WO2005107871A3 (en) Pyrroloquinoline quinone drugs for treatment of cardiac injury
AU2003254846A1 (en) Preventive therapeutic composition for muscular fatigue, pulled muscle and disease attributed thereto
ZA200602579B (en) Pentafluorosulfanyl, benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same

Legal Events

Date Code Title Description
FG Grant or registration